GSKGlaxoSmithKlineFinished
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 177 (final count)
- Started
- Mar 3, 2022
- Main results expected
- Aug 19, 2024
- Fully finished
- Feb 10, 2026
- Results posted
- Oct 7, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With Grade ≥2 Corneal Events Assessed by Keratopathy Visual Acuity (KVA) Scale
Measured over: Up to 29.5 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05064358 · record last updated 2026-05-05 · checked 2026-11-09 15:47 UTC